Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 11,741,240 | 11,689,950 | 11,018,080 | 12,261,320 | 10,511,240 |
| Cost of Goods | 2,803,766 | 1,953,877 | 1,818,779 | 1,862,583 | 1,666,799 |
| Gross Profit | 8,937,476 | 9,736,073 | 9,199,297 | 10,398,740 | 8,844,442 |
| Operating Expenses | 5,229,641 | 4,649,357 | 3,726,666 | 5,154,582 | 3,859,878 |
| Operating Income | 3,708,601 | 5,087,593 | 5,473,410 | 5,244,737 | 4,985,363 |
| Interest Expense | -239,285 | 754,112 | 731,321 | 416,784 | 121,015 |
| Other Income | 48,076 | 808,260 | 483,267 | 243,872 | 203,854 |
| Pre-tax Income | 3,995,962 | 5,141,741 | 5,225,356 | 5,071,825 | 5,068,202 |
| Income Tax | 863,023 | 1,110,634 | 1,128,659 | 1,045,207 | 1,044,034 |
| Net Income Continuous | 3,132,940 | 4,031,106 | 4,096,697 | 4,026,618 | 4,024,167 |
| Net Income | $3,132,940 | $4,031,106 | $4,096,697 | $4,026,618 | $4,024,167 |
| EPS Basic Total Ops | 0.70 | 0.91 | 0.92 | 0.90 | 0.90 |
| EPS Basic Continuous Ops | 0.70 | 0.91 | 0.92 | 0.91 | 0.90 |
| EPS Diluted Total Ops | 0.70 | 0.91 | 0.92 | 0.90 | 0.90 |
| EPS Diluted Continuous Ops | 0.70 | 0.91 | 0.92 | 0.90 | 0.90 |
| EPS Diluted Before Non-Recurring Items | 1.02 | 0.97 | 0.92 | 0.91 | 0.90 |
| EBITDA(a) | $4,962,330 | $5,864,822 | $6,013,824 | $5,965,065 | $5,338,726 |